2,2'-azobis-(4-methoxy-2,4-dimethylvaleronitrile)

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,2'-azobis-(4-methoxy-2,4-dimethylvaleronitrile)
• 英文别名: meso-2,2'-azobis(2,4-dimethyl-4-methoxyvaleronitrile)；2,2'-azobis(2,4-dimethyl-4-methoxyvaleronitrile)；2,2'-azobis(4-methoxy-2,4-dimethylvaleronitrile)；2,2'-azobis(2-cyano-4-methyl-4-methoxypentane)；V-70H；V-70
• 化学式: C₁₆H₂₈N₄O₂
• 分子量: 308.424
• InChiKey: PFHOSZAOXCYAGJ-FMQUCBEESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.63
• 重原子数：
  22.0
• 可旋转键数：
  8.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  90.76
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  2,2'-azobis-(4-methoxy-2,4-dimethylvaleronitrile) 在 phosphate buffered saline 、 phosphatidylcholine liposomes 作用下， 生成
  参考文献：
  名称：

  Minimizing Tocopherol-Mediated Radical Phase Transfer in Low-Density Lipoprotein Oxidation with an Amphiphilic Unsymmetrical Azo Initiator

  摘要：

  The antioxidant alpha -tocopherol (alpha -TOH) has been found to act as a pro-oxidant under many in vitro conditions. The observed tocopoherol-mediated peroxidation (TMP) is dependent on two primary factors. (1) Chain transfer: alpha -TO. radical reacts with lipid to form lipid peroxyl radicals. (2) Phase transfer: alpha -TOH can transport radical character into the lipoprotein. Given the limitations of existing initiators, there is a need for new compounds that avoid the requirement for alpha -TOH to act as a phase-transfer agent. We report here a study showing that the new unsymmetrical azo compound, C-8, initiates LDL lipid peroxidation without requirement for alpha -TOH. This initiator provides a steady source of free amphiphilic peroxyl radicals that efficiently initiates oxidation of alpha -TOH-depleted LDL at a rate comparable to that reported for the very reactive hydroxyl radical ((OH)-O-.). With other initiators tested, unsymmetrical C-12 and C-16 and symmetrical C-0 and MeOAMVN, alpha -TOH-depleted LDL displayed significant resistance to oxidation. Results indicate that the amphiphilic nature of the unsymmetrical initiators increases their partitioning into lipoprotein depending on the hydrocarbon chain length, and the symmetrical azo initiators C-0 and MeOAMVN primarily remain in the aqueous phase. Evidence suggests that even when the phase-transfer activity of alpha -TOH is limited, with the use of an initiator such as C-8, the mechanism of peroxidation remains controlled by TMP chain-transfer activity.

  DOI：

  10.1021/ja010060k
• 作为试剂：
  描述：

  丙烯醛 、 2,3,4,6-四乙酰氧基-alpha-D-吡喃葡萄糖溴化物 在 三正丁基氢锡 、 2,2'-azobis-(4-methoxy-2,4-dimethylvaleronitrile) 作用下， 以 乙醚 为溶剂， 反应 22.0h， 以50%的产率得到3-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)propianaldehyde
  参考文献：
  名称：

  Efficient stereoselective synthesis of α-C-glycopyranosides using 2,2′-azobis(2,4-dimethyl-4-methoxyvaleronitrile) [V-70]

  摘要：

  Efficient synthesis of alpha-C-glycopyranosides through a radical addition reaction using 2.2'-azobis(2,4-dimethyl-4-methoxyvaleronitrile) [V-70] as an initiator under mild condition was developed. This method made it possible to completely control the stereocenter at the anomeric position and obtain only the alpha-anomer in high yield compared with AIBN, Et3B, and photo irradiation methods. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00587-6

文献信息

• Benzofuran derivatives useful as inhibitors of bone resorption
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05858995A1

  公开（公告）日：1999-01-12

  This invention relates to a novel heterocyclic compound represented by formula (I), wherein each symbol is as defined in the specification and a pharmaceutically acceptable salt thereof which are the inhibitors of bone resorption and bone metabolism, to processes for preparation thereof, to a pharmaceutical composition comprising the same and to a method for the treatment of diseases caused by abnormal bone metabolism in human being or an animal.

  这项发明涉及一种由式(I)表示的新型杂环化合物，其中每个符号如规范中定义的，并且其药学上可接受的盐，这些化合物是骨吸收和骨代谢的抑制剂，涉及其制备方法，包括相同化合物的药物组合物，以及用于治疗人类或动物因异常骨代谢引起的疾病的方法。
• ENGINEERED CELLS AND AGENT COMPOSITIONS FOR THERAPEUTIC AGENT DELIVERY AND TREATMENTS USING SAME
  申请人：UNIVERSITY OF WASHINGTON

  公开号：US20200276318A1

  公开（公告）日：2020-09-03

  Provided herein are engineered cells and methods for engineering cells to deliver a therapeutic agent, e.g., a small molecule, peptide or other drug, to a cell or tissue to be treated.

  本文提供了经过工程改造的细胞以及用于工程改造细胞以传递治疗剂的方法，例如小分子、肽或其他药物，以传递到待治疗的细胞或组织。
• Process for producing acrylic acid derivative
  申请人：Nippon Soda Co. Ltd

  公开号：US20040152894A1

  公开（公告）日：2004-08-05

  Processes for producing a compound represented by the formula (1), which includes an acrylic acid derivative and is useful as an agricultural chemical or medicine. One of the processes comprises the step of formulating a compound (3) and converting the OH of the resultant compound (2) into OR″. The first step comprises reacting a formic or orthoformic ester in the presence of a Lewis acid and a base. The second step comprises reacting the compound with R″OH or with R″OH and CH(OR″) 3 under acidic conditions or using a phase-transfer catalyst in a two-phase system and regulating the base and the concentration thereof to stereoselectively synthesize the target compound. In another, process, the compound is efficiently produced without isolating the compound. The compound can also be produced without the compound (2). 1

  生产一种由化学式（1）表示的化合物的过程，该化合物包括丙烯酸衍生物，可用作农药或药物。其中一个过程包括将化合物（3）配制并将所得化合物（2）的羟基转化为OR″。第一步包括在Lewis酸和碱的存在下反应甲酸酯或正甲酸酯。第二步包括在酸性条件下将化合物与R″OH或与R″OH和CH(OR″)3反应，或者在两相系统中使用相转移催化剂，并调节碱及其浓度以立体选择性地合成目标化合物。在另一个过程中，该化合物可以在不分离该化合物的情况下高效生产。该化合物也可以在不使用化合物（2）的情况下生产。
• Quinoline compounds as H.sup.+ -ATPases
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06008230A1

  公开（公告）日：1999-12-28

  This invention relates to a quinoline compound of the formula: ##STR1## wherein R.sup.1 is a pyridyl group or aryl, each of which may be substituted with suitable substituent(s), A is --COHN-- or --NHCO--, n is an integer of 0 or 1, and ##STR2## is a group of the formula: ##STR3## In which R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined, and pharmaceutically acceptable salt thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prevention and/or the treatment of bone diseases caused by abnormal bone metabolism in human being or animals.

  这项发明涉及一种喹啉化合物，其化学式为：##STR1## 其中R.sup.1是吡啶基或芳基，每个基可能被适当的取代基取代，A是--COHN--或--NHCO--，n是0或1的整数，而##STR2## 是一个化学式为：##STR3## 的基团，其中R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.7如定义，以及其药学上可接受的盐，制备方法，包含相同化合物的药物组合物，以及用于预防和/或治疗由人类或动物骨骼异常代谢引起的骨病的方法。
• Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05994368A1

  公开（公告）日：1999-11-30

  This invention relates to a compound of the formula: ##STR1## wherein Z is a group of the formula: ##STR2## in which X.sup.1 is N or C--R.sup.1, X.sup.2 is N or C--R.sup.9, X.sup.3 is N or C--R.sup.2, R.sup.1 is lower alkyl, R.sup.2 is hydrogen, lower alkyl, etc., R.sup.9 is hydrogen or lower alkyl, R.sup.3 is halogen, etc., R.sup.4 is halogen, etc., R.sup.5 is a group of the formula: ##STR3## A is lower alkylene, and Y is O, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods to using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

  这项发明涉及以下化合物的公式：##STR1## 其中 Z 是以下公式的一个基团：##STR2## 其中 X^1 是 N 或 C--R^1，X^2 是 N 或 C--R^9，X^3 是 N 或 C--R^2，R^1 是较低的烷基，R^2 是氢，较低的烷基等，R^9 是氢或较低的烷基，R^3 是卤素等，R^4 是卤素等，R^5 是以下公式的一个基团：##STR3## A 是较低的烷基，Y 是 O 等，以及其药学上可接受的盐，制备方法，包含相同化合物的药物组合物，以及在人类或动物中在预防和/或治疗激肽酶或其类似物介导的疾病中治疗使用相同的方法。

表征谱图